Hemostatic and thrombotic markers in patients with hemoglobin E/β-thalassemia disease

• Main Authors: Pantep Angchaisuksiri, Vichai Atichartakarn, Katcharin Aryurachai, Napaporn Archararit, Suporn Chuncharunee, Arjit Tiraganjana, Sasivimol Rattanasiri
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/24689

Increased frequency of thrombosis has been observed in patients with hemoglobin E/β-thalassemia (Hb E/β-thal) disease, particularly those who have previously been splenectomized. We compared various hemostatic and thrombotic markers in blood from 15 Hb E/β-thal patients who were not splenectomized (NS), 15 who had been splenectomized (S), and 15 normal controls (NC). Levels of plasma thrombin-antithrombin, β2 thromboglobulin, C-reactive protein, tissue plasminogen activator antigen were significantly higher in the S group than in either the NS or the NC groups, and levels of prothrombin fragment 1.2 were significantly higher in the S than in the NC group. Levels of plasminogen activator inhibitor-1 antigen were significantly higher in the S than in the NS group. Levels of protein C, protein S, antithrombin, and fibrinogen were significantly lower in the S and NS groups than in the NC group. Plasma lipoprotein(a) levels in the S and NS groups were not statistically different from NC. Our findings indicated that there is evidence of chronic low-grade coagulation and platelet activation, chronic low-grade inflammation, endothelial cell injury, impaired fibrinolysis, and decreased naturally occurring anticoagulants in splenectomized Hb E/β-thal patients. These changes may account for the increased risk of thrombosis in these patients. © 2007 Wiley-Liss, Inc.